This article is more than 5 years old. Information may no longer be current.

VIDEO: Speaker discusses targeted treatment for melanoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — Jeffrey A. Sosman, MD, offered updates in the treatment of BRAF V600–mutant melanoma in light of greater use of immunotherapy at HemOnc Today Melanoma and Cutaneous Malignancies.

The MAP kinase pathway is activated in more than 90% of melanomas, according to Sosman, who is co-director of the translational research program and director of the melanoma program at Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Sosman also discussed options for NRAS–mutated melanoma and the role of MEK inhibition.

“MAP kinase needs to be there as any part of therapy, and immune therapy is certainly a component,” he said. “There are some other ways besides CDK4/6 inhibition that are quite interesting and, quite honestly, if immune therapy hadn’t overwhelmed the field, I think there would be a lot of work and trials looking at these as an alternate.”

Reference:

Sosman JA, et al. Current status of MAP kinase targeting for BRAF–mutated melanoma. Presented at: HemOnc Today Melanoma and Cutaneous Malignancies; March 24-25, 2017; New York.

Disclosure: Sosman reports consultant roles with Array, Bristol-Myers Squibb and Genentech.